

Playing our part in the fight against COVID-19

The COVID-19 pandemic presents significant challenges to people across the world. As part of the Novartis commitment to building a healthier tomorrow, we are taking urgent action to help support health systems and broader society, both globally and here in the UK.

Novartis UK support

Our response to support the NHS and UK society is focused on three core areas:

Patients and research



We are working closely with the Department of Health and Social Care to ensure **uninterrupted supply of medicines** and to meet the unprecedented demand

We are **rapidly evaluating our existing products**

as candidates for the potential treatment of COVID-19 and supporting the NHS in their investigations, as well as accelerating R&D on novel therapeutics



Our associates



We are **prioritising associates' health and wellbeing** through an extensive support programme, remote working advice and training sessions. Support for associates will continue as the lockdown is lifted



In recognition of associates' desire to help, our volunteering programme enables associates to spend up to 12 paid days contributing their time and expertise to any voluntary group


12 paid days



Our communities



The **relaunched Novartis UK Health Hub 2020**



will provide funding support for companies looking to accelerate digital solutions to help address the medium to long term challenges for the NHS presented by COVID-19

We are partnering with the NHS to support them through



wellbeing and resilience programmes

Novartis global support

Across our Novartis global functions, we have mobilised R&D capabilities, medicines, clinical trials expertise and philanthropic aid to help the worldwide fight against COVID-19

Research & development



We are partnering with multi-stakeholder consortia, including the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome Trust and MasterCard, to

leverage our capabilities in discovery, development and scale-up manufacturing




We are committed to donating **up to 130 million doses** of a candidate treatment for COVID-19

We have also **provided open access to our compound libraries** to support the global pandemic response



Community fund

The Novartis COVID-19 Response Fund will provide



USD 20 million to support communities

around the world most impacted by COVID-19



Pricing commitment



SANDOZ A Novartis Division

Sandoz, the Novartis generics and biosimilars division, is

maintaining prices

on a basket of essential medicines that may help in the treatment of COVID-19

